{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:14:20Z","timestamp":1783606460225,"version":"3.55.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304420"],"award-info":[{"award-number":["82304420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ40576"],"award-info":[{"award-number":["2023JJ40576"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019310","name":"Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bioorg.2024.107251","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T11:24:09Z","timestamp":1709205849000},"page":"107251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Small-molecule modulators of tumor immune microenvironment"],"prefix":"10.1016","volume":"145","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-4727","authenticated-orcid":false,"given":"Guotao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"issue":"127","key":"10.1016\/j.bioorg.2024.107251_b0010","doi-asserted-by":"crossref","first-page":"127ps8","DOI":"10.1126\/scitranslmed.3003634","article-title":"Raising the bar: the curative potential of human cancer immunotherapy","volume":"4","author":"Rosenberg","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0015","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1038\/cti.2014.7","article-title":"Clinical application of genetically modified T cells in cancer therapy","volume":"3","author":"Kershaw","year":"2014","journal-title":"Clin. Transl. Immunol."},{"issue":"7378","key":"10.1016\/j.bioorg.2024.107251_b0020","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.11.010","article-title":"Promising approaches in cancer immunotherapy","volume":"225","author":"Taefehshokr","year":"2020","journal-title":"Immunobiology"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3892\/ijo.2022.5302","article-title":"Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (review)","volume":"60","author":"Lu","year":"2022","journal-title":"Internet J. Oncol."},{"key":"10.1016\/j.bioorg.2024.107251_b0035","doi-asserted-by":"crossref","unstructured":"A.W. Hahn, D.M. Gill, N. Agarwal, B.L. Maughan, PD-1 checkpoint inhibition: Toxicities and management, Urol. Oncol.: Semin. Orig. 35(12) (2017) 701-707. https:\/\/doi.org\/10.1016\/j.urolonc.2017.08.005.","DOI":"10.1016\/j.urolonc.2017.08.005"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/1061186X.2018.1440400","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy","volume":"27","author":"Li","year":"2019","journal-title":"J. Drug Targeting."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.bioorg.2024.107251_b0055","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2024.107251_b0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2017.35.15_suppl.105","article-title":"A phase ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bioorg.2024.107251_b0070","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2174\/1389557522666220930154527","article-title":"Small-molecule drugs in immunotherapy","volume":"23","author":"Hao","year":"2023","journal-title":"Mini-Rev. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/intimm\/8.5.773","article-title":"Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes","volume":"8","author":"Nishimura","year":"1996","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0080","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107251_b0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijcard.2006.03.043","article-title":"Cardiovascular disease and risk factors among 345 adults in rural India - the Andhra Pradesh rural health initiative","volume":"116","author":"Chow","year":"2007","journal-title":"Int J Cardiol."},{"issue":"6332","key":"10.1016\/j.bioorg.2024.107251_b0105","doi-asserted-by":"crossref","first-page":"1428-+","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science."},{"issue":"7528","key":"10.1016\/j.bioorg.2024.107251_b0110","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107251_b0115","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1093\/annonc\/mdy451","article-title":"Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial","volume":"29","author":"Gaiser","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bioorg.2024.107251_b0120","article-title":"Simultaneous determination of a novel PD-L1 inhibitor, IMMH-010, and its active metabolite, YPD-29B, in rat biological matrices by polarity-switching liquid chromatography-tandem mass spectrometry: application to ADME studies","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0125","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1021\/acs.jmedchem.9b00312","article-title":"Discovery of [1,2,4]Triazolo[4,3-a]pyridines as potent inhibitors targeting the programmed cell death-1\/programmed cell death-ligand 1 interaction","volume":"62","author":"Qin","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113998","article-title":"Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1\/programmed cell death-ligand 1 (PD-1\/PD-L1) interaction","volume":"229","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2024.107251_b0135","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1021\/acs.jmedchem.0c01260","article-title":"Di-bromo-based small-molecule inhibitors of the PD-1\/PD-L1 immune checkpoint","volume":"63","author":"Konieczny","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116575","article-title":"Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1\/programmed cell death-ligand 1 interaction (vol 46, 116370, 2021)","volume":"54","author":"Fang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113001","article-title":"Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1\/ programmed cell death-ligand 1 (PD-1\/PD-L1) interaction","volume":"211","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11030-021-10208-4","article-title":"Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1\/ programmed cell death-ligand 1 immune checkpoint","volume":"26","author":"Zhu","year":"2022","journal-title":"Mol Divers"},{"issue":"22","key":"10.1016\/j.bioorg.2024.107251_b0155","doi-asserted-by":"crossref","first-page":"16687","DOI":"10.1021\/acs.jmedchem.1c01422","article-title":"synthesis, and pharmacological evaluation of biaryl-containing PD-1\/PD-L1 interaction inhibitors bearing a unique difluoromethyleneoxy linkage","volume":"64","author":"Song","year":"2021","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2024.107251_b0160","doi-asserted-by":"crossref","first-page":"13825","DOI":"10.1021\/acs.jmedchem.0c01329","article-title":"Design, synthesis, and biological evaluation of linear aliphatic amine-linked triaryl derivatives as potent small-molecule inhibitors of the programmed cell death-1\/programmed cell death-ligand 1 interaction with promising antitumor effects in vivo","volume":"63","author":"Guo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113377","article-title":"Design, synthesis, and structure-activity relationship of programmed cell death-1\/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold","volume":"217","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2024.107251_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127328","article-title":"Design, synthesis and biological evaluation of 2-methyl-(1,1 '-biphenyl)-pyrimidine conjugates","volume":"30","author":"Chen","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105034","article-title":"Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo [4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1\/PD-L1 interaction","volume":"114","author":"Dai","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128403","article-title":"Design, synthesis, and structure-activity relationship of PD-1\/PD-L1 inhibitors with a benzo[d]isoxazole scaffold","volume":"52","author":"Huang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111856","article-title":"Discovery of the programmed cell death-1\/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold","volume":"186","author":"Qin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128647","article-title":"Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1\/PD-L1 interaction","volume":"63","author":"Meng","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0195","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1021\/acs.jmedchem.0c01958","article-title":"Discovery of 4-arylindolines containing a thiazole moiety as potential antitumor agents inhibiting the programmed cell death-1\/programmed cell death-ligand 1 interaction","volume":"64","author":"Qin","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0200","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112377","article-title":"Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1","volume":"199","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2024.107251_b0210","doi-asserted-by":"crossref","first-page":"15946","DOI":"10.1021\/acs.jmedchem.0c01684","article-title":"Discovery of novel and highly potent resorcinol dibenzyl ether-based PD-1\/PD-L1 inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0215","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1021\/acs.jmedchem.1c00370","article-title":"Design, synthesis, and evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl derivatives as PD-1\/PD-L1 inhibitors with potent anticancer efficacy in vivo","volume":"64","author":"OuYang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107251_b0220","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1021\/acs.jmedchem.0c00574","article-title":"Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1\/programmed cell death-ligand 1 interaction as potential anticancer agents","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114522","article-title":"Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1\/PD-L1 with benign toxicity profiles for cancer treatment","volume":"188","author":"Cao","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107251_b0230","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1021\/acs.jmedchem.1c00392","article-title":"Syntheses, biological evaluations, and mechanistic studies of Benzo[c][1,2,5]oxadiazole derivatives as potent PD-L1 inhibitors with in vivo antitumor activity","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/j.bioorg.2024.107251_b0235","doi-asserted-by":"crossref","first-page":"21181","DOI":"10.1021\/acsomega.0c02916","article-title":"Synthesis and evaluation of biphenyl-1,2,3-triazol-benzonitrile derivatives as PD-1\/PD-L1 inhibitors","volume":"5","author":"Narva","year":"2020","journal-title":"Acs Omega"},{"issue":"21","key":"10.1016\/j.bioorg.2024.107251_b0240","doi-asserted-by":"crossref","first-page":"16020","DOI":"10.1021\/acs.jmedchem.1c01409","article-title":"Interfering with the tumor-immune interface: making way for triazine-based small molecules as novel PD-L1 inhibitors","volume":"64","author":"Russomanno","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0245","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1021\/acsmedchemlett.1c00033","article-title":"Design, synthesis, and biological evaluation of imidazopyridines as PD-1\/PD-L1 antagonists","volume":"12","author":"Butera","year":"2021","journal-title":"Acs Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107251_b0250","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.bmcl.2019.07.027","article-title":"Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 interaction","volume":"29","author":"Kawashita","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107251_b0255","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1021\/acs.jmedchem.9b00795","article-title":"Design, synthesis, evaluation, and structural studies of C(2)-symmetric small molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein-protein interaction","volume":"62","author":"Basu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113637","article-title":"Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1\/programmed cell death-ligand 1 interaction","volume":"223","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107251_b0265","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1021\/acs.jmedchem.1c00957","article-title":"Terphenyl-based small-molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein-protein interaction","volume":"64","author":"Muszak","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0270","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/acs.jmedchem.1c00010","article-title":"Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell death-1\/programmed cell death-ligand 1 interaction","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0275","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3390\/molecules26113347","article-title":"Discovery of novel small-molecule inhibitors of PD-1\/PD-L1 interaction via structural simplification strategy","volume":"26","author":"Zhang","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0280","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/14786419.2019.1586698","article-title":"Phenolic compounds from cultivated Glycyrrhiza uralensis and their PD-1\/PD-L1 inhibitory activities","volume":"35","author":"Bao","year":"2021","journal-title":"Nat. Prod. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0285","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3390\/molecules25092068","article-title":"Inhibition of programmed death receptor-1\/programmed death ligand-1 interactions by ginsenoside metabolites","volume":"25","author":"Yim","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0290","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/138955712802762374","article-title":"Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors","volume":"12","author":"Delfourne","year":"2012","journal-title":"Mini-Rev. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0295","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2005.09.032","article-title":"Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism","volume":"338","author":"Takikawa","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107251_b0300","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues (vol 3, pg 161, 2015)","volume":"8","author":"Theate","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0305","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3171\/2008.10.JNS081141","article-title":"Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy laboratory investigation","volume":"111","author":"Miyazaki","year":"2009","journal-title":"J. Neurosurg."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107251_b0310","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0315","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0320","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR a novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0325","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107251_b0330","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0335","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jir.2006.26.53","article-title":"Upregulation of IFN-gamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells","volume":"26","author":"Shirey","year":"2006","journal-title":"J Interf Cytok Res"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107251_b0340","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.intimp.2011.02.005","article-title":"L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species","volume":"11","author":"Song","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"66","key":"10.1016\/j.bioorg.2024.107251_b0345","article-title":"IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery (vol 6, pg 7575, 2016)","volume":"6","author":"Qian","year":"2016","journal-title":"Rsc Adv."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107251_b0350","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1039\/C7MD00109F","article-title":"Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry","volume":"8","author":"Coletti","year":"2017","journal-title":"Medchemcomm"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0355","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1039\/C9MD00208A","article-title":"Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"10","author":"Wang","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.bioorg.2024.107251_b0360","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejmech.2017.11.088","article-title":"Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy","volume":"143","author":"Weng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0365","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/0003-9861(91)90142-6","article-title":"1-methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase","volume":"291","author":"Cady","year":"1991","journal-title":"Arch. Biochem. Biophys."},{"issue":"23","key":"10.1016\/j.bioorg.2024.107251_b0370","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","article-title":"Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate","volume":"60","author":"Crosignani","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0375","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.21873\/anticanres.15004","article-title":"Structure-activity relationship of indomethacin derivatives as IDO1 inhibitors","volume":"41","author":"Obata","year":"2021","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0380","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1021\/acsmedchemlett.7b00488","article-title":"Identification of potent indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors based on a phenylimidazole scaffold","volume":"9","author":"Brant","year":"2018","journal-title":"Acs Med. Chem. Lett."},{"issue":"14","key":"10.1016\/j.bioorg.2024.107251_b0385","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/cmdc.202100107","article-title":"A series of 2-((1-phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"16","author":"Zheng","year":"2021","journal-title":"Chemmedchem"},{"issue":"14","key":"10.1016\/j.bioorg.2024.107251_b0390","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.9b00662","article-title":"Discovery of clinical candidate (1R,4r)-4-((R)-2-((S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1","volume":"62","author":"Kumar","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0395","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/acs.jmedchem.5b01390","article-title":"Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1","volume":"59","author":"Peng","year":"2016","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107251_b0400","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/acsmedchemlett.9b00114","article-title":"Discovery of imidazoisoindole derivatives as highly potent and orally active indoleamine-2,3-dioxygenase inhibitors","volume":"10","author":"Tu","year":"2019","journal-title":"Acs Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107251_b0405","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.bbapap.2011.07.023","article-title":"Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors","volume":"1814","author":"Meininger","year":"2011","journal-title":"Biochim. Biophys. Acta."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0410","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/ml500247w","article-title":"Crystal structures and structure activity relationships of imidazothiazole derivatives as IDO1 inhibitors","volume":"5","author":"Tojo","year":"2014","journal-title":"Acs Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0415","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bmcl.2018.01.032","article-title":"A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: synthesis, biological investigation and docking studies","volume":"28","author":"Griglio","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0420","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24101874","article-title":"Synthesis, Docking and biological evaluation of a novel class of imidazothiazoles as IDO1 inhibitors","volume":"24","author":"Serafini","year":"2019","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107251_b0425","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/acs.jmedchem.9b01809","article-title":"Discovery of highly potent benzimidazole derivatives as indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors: from structure-based virtual screening to in vivo pharmacodynamic activity","volume":"63","author":"Serafini","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0430","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1021\/acs.jmedchem.0c01968","article-title":"Azole-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"64","author":"Rohrig","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0435","doi-asserted-by":"crossref","first-page":"18455","DOI":"10.1038\/s41598-019-54963-9","article-title":"4,5-disubstituted 1,2,3-triazoles: effective inhibition of indoleamine 2,3-dioxygenase 1 enzyme regulates T cell activity and mitigates tumor growth","volume":"9","author":"Panda","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0440","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/ph14030265","article-title":"Novel selective IDO1 inhibitors with isoxazolo[5,4-d]pyrimidin-4(5H)-one scaffold","volume":"14","author":"Dolsak","year":"2021","journal-title":"Pharmaceuticals (basel)"},{"issue":"22","key":"10.1016\/j.bioorg.2024.107251_b0445","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/cmdc.202100446","article-title":"The [1,2,4]Triazolo[4,3-a]pyridine as a new player in the field of IDO1 catalytic holo-inhibitors","volume":"16","author":"Fallarini","year":"2021","journal-title":"Chemmedchem"},{"issue":"14","key":"10.1016\/j.bioorg.2024.107251_b0450","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.bmc.2017.05.017","article-title":"Identification and preliminary structure-activity relationships of 1-indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors","volume":"25","author":"Gao","year":"2017","journal-title":"Bioorgan. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0455","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (epacadostat), a highly potent and selective Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immunooncology","volume":"8","author":"Yue","year":"2017","journal-title":"Acs Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0460","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41467-017-01725-8","article-title":"Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1","volume":"8","author":"Lewis-Ballester","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107251_b0465","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejmech.2019.06.037","article-title":"Design, synthesis and antitumor study of a series of N-cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors","volume":"179","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112059","article-title":"Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors","volume":"189","author":"Song","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111629","article-title":"Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer","volume":"182","author":"Du","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2024.107251_b0480","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.2174\/1871520620666200604121225","article-title":"Design, synthesis and biological evaluation of novel 1,2,5-oxadiazol-3-carboximidamide derivatives as indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors","volume":"20","author":"Xia","year":"2020","journal-title":"Anti-Cancer Agents Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0485","first-page":"179","article-title":"Discovery of hydroxyamidine based inhibitors of IDO1 for cancer immunotherapy with reduced potential for glucuronidation, acs med","volume":"11","author":"Steeneck","year":"2020","journal-title":"Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0490","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1021\/acsmedchemlett.9b00344","article-title":"Discovery of amino-cyclobutarene-derived indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors for cancer immunotherapy","volume":"10","author":"Zhang","year":"2019","journal-title":"Acs Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0495","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejmech.2016.05.061","article-title":"Nitrobenzofurazan derivatives of N '-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1","volume":"121","author":"Paul","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0500","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/molecules22111936","article-title":"Synthesis and molecular modeling studies of N '-hydroxyindazolecarboximidamides as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"22","author":"Lee","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107251_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127963","article-title":"Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"40","author":"Jung","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0510","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bmcl.2016.12.015","article-title":"Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors","volume":"27","author":"Markwalder","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0515","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bmcl.2018.01.010","article-title":"Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"28","author":"Williams","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103356","article-title":"Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors","volume":"94","author":"Cai","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107251_b0525","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bmc.2019.03.005","article-title":"Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors","volume":"27","author":"Yang","year":"2019","journal-title":"Bioorgan. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2024.107251_b0530","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1016\/j.bmc.2019.05.048","article-title":"Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors","volume":"27","author":"Hu","year":"2019","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0535","doi-asserted-by":"crossref","unstructured":"C.E. Blunt, C. Torcuk, Y. Liu, W. Lewis, D. Siegel, D. Ross, C.J. Moody, Synthesis and intracellular redox cycling of natural quinones and their analogues and identification of indoleamine-2,3-dioxygenase (IDO) as potential target for anticancer activity, Angew. Chem., Int. Ed. 54(30) (2015) 8740-8745. https:\/\/doi.org\/10.1002\/anie.201503323.","DOI":"10.1002\/anie.201503323"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0540","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1021\/np060111x","article-title":"Indoleamine 2,3-dioxygenase inhibitors from the northeastern pacific marine hydroid garveia annulata","volume":"69","author":"Pereira","year":"2006","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2024.107251_b0545","doi-asserted-by":"crossref","unstructured":"C. Carvalho, D. Siegel, M. Inman, R. Xiong, D. Ross, C.J. Moody, Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation, Org. Biomol. Chem. 12(17) (2014) 2663-2674. https:\/\/doi.org\/10.1039\/c3ob42258e.","DOI":"10.1039\/c3ob42258e"},{"issue":"50","key":"10.1016\/j.bioorg.2024.107251_b0550","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1021\/ja067211+","article-title":"Exiguamine a, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua","volume":"128","author":"Brastianos","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0555","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bmcl.2012.11.036","article-title":"Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine a","volume":"23","author":"Dolusic","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126901","article-title":"Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors","volume":"30","author":"Kong","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113631","article-title":"Design, synthesis and biological evaluation of exiguamine a analogues as IDO1 inhibitors","volume":"223","author":"Dong","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.03.044","article-title":"Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors","volume":"89","author":"Ding","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112703","article-title":"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)","volume":"207","author":"Pan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0580","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejmech.2018.08.013","article-title":"Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors","volume":"157","author":"Pan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107251_b0585","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/molecules24061059","article-title":"Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product","volume":"24","author":"Zhao","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107251_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114294","article-title":"Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase","volume":"235","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0595","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1535-7163.MCT-20-0251","article-title":"Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor","volume":"20","author":"Balog","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0600","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1021\/acsmedchemlett.0c00668","article-title":"Discovery and preclinical evaluation of BMS-986242, a potent, selective inhibitor of indoleamine-2,3-dioxygenase 1","volume":"12","author":"Cherney","year":"2021","journal-title":"Acs Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127744","article-title":"Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors","volume":"33","author":"Steeneck","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0610","doi-asserted-by":"crossref","unstructured":"L.P. Zhang, E.C. Cherney, X. Zhu, T.A. Lin, J. Gullo-Brown, D. Maley, K. Johnston-Allegretto, L. Kopcho, M. Fereshteh, C. Huang, X. Li, S.C. Traeger, G. Dhar, A. Anandam, S. Mahankali, S. Padmanabhan, P. Rajanna, V. Murali, T. Mariappan, R. Borzilleri, G. Vite, J.T. Hunt, A. Balog, Discovery of imidazopyridines as potent inhibitors of indoleamine 2,3-dioxygenase 1 for cancer immunotherapy., Acs Med. Chem. Lett. 12(3) (2021) 494-501. https:\/\/doi.org\/10.1021\/acsmedchemlett.1c00014.","DOI":"10.1021\/acsmedchemlett.1c00014"},{"key":"10.1016\/j.bioorg.2024.107251_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127738","article-title":"Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold","volume":"33","author":"Kinzel","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107251_b0620","doi-asserted-by":"crossref","first-page":"11302","DOI":"10.1021\/acs.jmedchem.1c00679","article-title":"Discovery of IACS-9779 and IACS-70465 as potent inhibitors targeting indoleamine 2,3-dioxygenase 1 (IDO1) apoenzyme","volume":"64","author":"Hamilton","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0625","doi-asserted-by":"crossref","unstructured":"D. Li, Y. Deng, A. Achab, I. Bharathan, B.A. Hopkins, W. Yu, H. Zhang, S. Sanyal, Q. Pu, H. Zhou, K. Liu, J. Lim, X. Fradera, C.A. Lesburg, A. Lammens, T.A. Martinot, R.D. Cohen, A.C. Doty, H. Ferguson, E.B. Nickbarg, M. Cheng, P. Spacciapoli, P. Geda, X. Song, N. Smotrov, P. Abeywickrema, C. Andrews, C. Chamberlin, O. Mabrouk, P. Curran, M. Richards, P. Saradjian, J.R. Miller, I. Knemeyer, K.M. Otte, S. Vincent, N. Sciammetta, A. Pasternak, D.J. Bennett, Y. Han, Carbamate and N-pyrimidine mitigate amide hydrolysis: structure-based drug design of tetrahydroquinoline IDO1 inhibitors., Acs Med. Chem. Lett. 12(3) (2021) 389-396. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00525.","DOI":"10.1021\/acsmedchemlett.0c00525"},{"key":"10.1016\/j.bioorg.2024.107251_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128314","article-title":"Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold","volume":"49","author":"Yu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107251_b0635","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1021\/acs.jmedchem.1c01670","article-title":"Oxetane promise delivered: discovery of long-acting IDO1Inhibitors suitable for Q3W Oral or parenteral dosing","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0640","doi-asserted-by":"crossref","unstructured":"Q.L. Pu, H.J. Zhang, L.Q. Guo, M.G. Cheng, A.C. Doty, H. Ferguson, X. Fradera, C.A. Lesburg, M.A. McGowan, J.R. Miller, P. Geda, X.L. Song, K. Otte, N. Sciammetta, N. Solban, W.S. Yu, D.L. Sloman, H. Zhou, A. Lammens, L. Neumann, D.J. Bennett, A. Pasternak, Y.X. Han, Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors, Acs Med. Chem. Lett. 11(8) (2020) 1548-1554. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00195.","DOI":"10.1021\/acsmedchemlett.0c00195"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0645","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1021\/acsmedchemlett.1c00531","article-title":"Novel substituted piperazine amide compounds as Indoleamine-2,3-dioxygenase (IDO) inhibitors","volume":"12","author":"Sabnis","year":"2021","journal-title":"Acs Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0650","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/14756366.2018.1480614","article-title":"Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation","volume":"34","author":"Xu","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0655","article-title":"Inhibitory investigation of niacin derivatives on metalloenzyme indoleamine 2,3-dioxygenase 1 for its immunomodulatory function","volume":"13","author":"Yan","year":"2021","journal-title":"Metallomics"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0660","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","article-title":"TGFbeta signaling in growth control, cancer, and heritable disorders","volume":"103","author":"Massague","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0665","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14728222.2020.1744568","article-title":"TGF-beta: a master immune regulator","volume":"24","author":"Larson","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"issue":"14","key":"10.1016\/j.bioorg.2024.107251_b0670","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-06-0952","article-title":"Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy","volume":"12","author":"Biswas","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0675","first-page":"128","article-title":"MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1","volume":"54","author":"Jiang","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0680","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-beta signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107251_b0685","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.immuni.2006.07.011","article-title":"Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms","volume":"25","author":"Li","year":"2006","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0690","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrm2262","article-title":"Extracellular control of TGFbeta signaling in vascular development and disease","volume":"8","author":"ten Dijke","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107251_b0695","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0700","first-page":"550","article-title":"Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma","volume":"61","author":"Lohr","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107251_b0705","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/bonekey.2012.96","article-title":"The role of TGF-beta in bone metastasis: novel therapeutic perspectives","volume":"1","author":"Buijs","year":"2012","journal-title":"Bonekey Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107251_b0710","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14728222.2019.1636034","article-title":"Blockade of TGF-beta signaling: a potential target for cancer immunotherapy?","volume":"23","author":"Ungefroren","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0715","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","article-title":"Semi-mechanistic modeling of the tumor growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice","volume":"44","author":"Bueno","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0720","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"Jin","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107251_b0725","first-page":"955","article-title":"Elevated ASCL2 expression in breast cancer is associated with the poor prognosis of patients","volume":"7","author":"Xu","year":"2017","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0730","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1349-7006.2005.00103.x","article-title":"The ALK-5 inhibitor A-83-01 inhibits smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta","volume":"96","author":"Tojo","year":"2005","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107251_b0735","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1021\/jm0509905","article-title":"Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor","volume":"49","author":"Gellibert","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113311","article-title":"Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5\/p38\u03b1 MAP inhibitors","volume":"216","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2024.107251_b0745","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bmcl.2019.07.015","article-title":"Synthesis and biological evaluation of novel benzo[c] [1,2,5]thiadiazol-5-yl and thieno [3,2-c] - pyridin-2-yl imidazole derivatives as ALK5 inhibitors","volume":"29","author":"Guo","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bioorg.2024.107251_b0750","doi-asserted-by":"crossref","unstructured":"M.S. Park, H.J. Park, Y.J. An, J.H. Choi, G. Cha, H.J. Lee, S.J. Park, P.M. Dewang, D.K. Kim, Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors, J. Enzyme Inhib. Med. Chem. 35(1) (2020) 702-712. https:\/\/doi.org\/ 10.1080\/14756366.2020.1734799.","DOI":"10.1080\/14756366.2020.1734799"},{"issue":"22","key":"10.1016\/j.bioorg.2024.107251_b0755","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1016\/j.bmcl.2015.09.058","article-title":"Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-\u03b2 type I receptor kinase","volume":"25","author":"Krishnaiah","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107251_b0760","first-page":"172","article-title":"Discovery of BMS-986260, a potent, selective, and orally bioavailable TGF\u03b2R1 inhibitor as an immuno-oncology agent, acs med","volume":"11","author":"Velaparthi","year":"2020","journal-title":"Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0765","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.bmcl.2012.01.066","article-title":"Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-beta type I receptor kinase","volume":"22","author":"Amada","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.bioorg.2024.107251_b0770","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1016\/j.bmc.2012.09.066","article-title":"5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-beta type I receptor inhibitors","volume":"20","author":"Amada","year":"2012","journal-title":"Bioorgan. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107251_b0775","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1016\/j.bmcl.2013.08.105","article-title":"Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-\u03b2 type I receptor (ALK5)","volume":"23","author":"Guo","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0780","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejmech.2014.09.002","article-title":"Design, synthesis and evaluation of small molecule imidazo[2,1-b] [1,3,4]thiadiazoles as inhibitors of transforming growth factor-beta type-I receptor kinase (ALK5)","volume":"93","author":"Patel","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107251_b0785","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGFbeta signaling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"16","key":"10.1016\/j.bioorg.2024.107251_b0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127339","article-title":"Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor inhibitors","volume":"30","author":"Tan","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128552","article-title":"Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as a novel, potent of ALK5 receptor inhibitors","volume":"61","author":"Wang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112354","article-title":"Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-beta type 1 receptor inhibitors","volume":"198","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2024.107251_b0805","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.joc.6b02230","article-title":"Application of pd-catalyzed cross-coupling reactions in the synthesis of 5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that inhibit ALK5 kinase","volume":"81","author":"Tenora","year":"2016","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2024.107251_b0810","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ejmech.2017.01.018","article-title":"ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles","volume":"127","author":"Reznickova","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107251_b0815","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bmc.2018.01.014","article-title":"Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFbetaRI)","volume":"26","author":"Harikrishnan","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107251_b0820","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.bmcl.2017.03.026","article-title":"Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b] pyridine ALK5 (activin receptor-like kinase 5) inhibitors","volume":"27","author":"Sabat","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0825","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejmech.2019.07.013","article-title":"Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives","volume":"180","author":"Zhu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0830","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/acsmedchemlett.8b00357","article-title":"Discovery of 4-azaindole inhibitors of TGF\u03b2RI as immuno-oncology agents","volume":"9","author":"Zhang","year":"2018","journal-title":"Acs Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107251_b0835","doi-asserted-by":"crossref","unstructured":"H. Wang, R.B. Sessions, S.S. Prime, D.K. Shoemark, S.J. Allen, W. Hong, S. Narayanan, I.C. Paterson, Identification of novel small molecule TGF-beta antagonists using structure-based drug design, J. Comput.-Aided Mol. Des. 27(4) (2013) 365-372. https:\/\/doi.org\/10.1007\/s10822-013-9651-9.","DOI":"10.1007\/s10822-013-9651-9"},{"key":"10.1016\/j.bioorg.2024.107251_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112042","article-title":"The development of a novel transforming growth factor-beta (TGF-beta) inhibitor that disrupts ligand-receptor interactions","volume":"189","author":"Wu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0845","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"7693","key":"10.1016\/j.bioorg.2024.107251_b0850","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature."},{"issue":"7693","key":"10.1016\/j.bioorg.2024.107251_b0855","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107251_b0860","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-017-02696-6","article-title":"Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy","volume":"9","author":"Ravi","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107251_b0865","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-beta and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol. Oncol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:21:52Z","timestamp":1783603312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":173,"alternative-id":["S0045206824001561"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107251","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-molecule modulators of tumor immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107251"}}